Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis
Jie-Ying Chen, Ya-Nan Cheng, Lei Han and 5 more
Cancer Biology & Medicine · 2015
doi:10.7497/j.issn.2095-3941.2015.0021 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<b>Objective:</b>A meta-analysis was performed to augment the insufficient data on the impact of mutative <i>EGFR</i> downstream phosphatidylinositol-3-kinase (<i>PI3K</i>) and mitogen-activated protein kinase (<i>MAPK</i>) pathways on the clinical efficiency of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment of non-small cell lung cancer (NSCLC) patients.<br/><b>Methods:</b>Network databases were explored in April, 2015. Papers that investigated the clinical outcomes of NSCLC patients treated with <i>EGFR</i>-TKIs according to the status of <i>K-ras</i> and/or <i>PIK3CA</i> gene mutation were included. A quantitative meta-analysis was conducted using standard statistical methods. Odds ratios (ORs) for objective response rate (ORR) and hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were calculated.<br/><b>Results:</b>Mutation in <i>K-ras</i> significantly predicted poor ORR[OR=0.22; 95% confidence interval (CI), 0.13-0.35], shorter PFS (HR=1.56; 95% CI, 1.27-1.92), and shorter OS (HR=1.59; 95% CI, 1.33-1.91) in NSCLC patients treated with <i>EGFR</i>-TKIs. Mutant PIK3CA significantly predicted shorter OS (HR=1.83; 95% CI, 1.05-3.20), showed poor ORR (OR=0.70; 95% CI, 0.22-2.18), and shorter PFS (HR=1.79; 95% CI, 0.91-3.53) in NSCLC patients treated with EGFR-TKIs.<br/><b>Conclusion:</b><i>K-ras</i> mutation adversely affected the clinical response and survival of NSCLC patients treated with EGFRTKIs. <i>PIK3CA</i> mutation showed similar trends. In addition to EGFR, adding <i>K-ras</i> and <i>PIK3CA</i> as routine gene biomarkers in clinical genetic analysis is valuable to optimize the effectiveness of EGFR-TKI regimens and identify optimal patients who will benefit from <i>EGFR</i>-TKI treatment.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.